So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the.

Slides:



Advertisements
Similar presentations
The PREVEND Study: Screening for micro-albuminuria
Advertisements

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson,
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
(IRbesartan in MicroAlbuminuria, Type 2 Diabetic Nephropathy Trial)
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
The case of microalbuminuria prevention: the ROADMAP study Department for Clinical Pharmacology and Hypertension Charité – University Medicine Berlin,
Lesley Stevens MD Tufts-New England Medical Center
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
Randomized, double-blind, multicenter, controlled trial.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Kimberly Dunbar, PA-S2 Follow-up of Cardiovascular Risk Markers in Hypertensive Patients Treated with Irbesartan: Results of the i-SEARCH Plus Registry.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.
Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Sickle Cell Trait With Chronic Kidney.
Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74 Ravi Retnakaran, Carole A Cull, Kerensa I Thorne, Amanda I Adler,
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Clinical Outcomes with Newer Antihyperglycemic Agents
Diabetes and CKD- The update
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
The Significance of Albuminuria
What should the Systolic BP treatment goal be in patients with CKD?
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 4: Managing progression of CKD
ACCORD Microvascular Outcomes
Mastery of Medicine in Diabetes Management Video Roundtable
HOPE Trial Urine Albumin/Creatinine Ratio (UACR)
Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications  Stefano Bianchi, MD, Roberto Bigazzi, MD, Vito.
HOPE: Heart Outcomes Prevention Evaluation study
Chapter 1: CKD in the General Population
The Anglo Scandinavian Cardiac Outcomes Trial
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure  Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu,
Diabetes Health Status Report
Elevated levels of various circulating amino acids (AAs) predict the development of Type 2 diabetes. In one prospective study, three branched-chain AAs.
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
Systolic Blood Pressure Intervention Trial (SPRINT)
The percentage of subjects with de novo development of renal function impairment (GFR
These slides highlight an educational report from a satellite symposium presented at the Annual Scientific Meeting of the Canadian Society of Internal.
Recent studies of ACE inhibition in renal disease
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Management of hypertension in patients with chronic kidney disease
Chapter 1: CKD in the General Population
Section I: RAS manipulation
Volume 83, Issue 2, Pages (February 2013)
American Journal of Kidney Diseases
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Presentation transcript:

So What is Albuminuria? An elevated urinary albumin excretion is a marker of endothelial dysfunction that symbolizes the kidney’s way to translate the existence of vascular damage

Increased All-Cause Morality with Albumin Creatinine Ratio Greater > 5 Kidney Int 2011;79:1341-1352

Strong Linear Relationship: Urine Albumin Creatinine with CV Mortality and Heart Failure Kidney Int 2011;79:1341-1352

Changes in Albuminuria Predict Major Clinical Outcomes in Diabetes Adjusted HRs and 95% CIs for study outcomes associated with 2-year fold changes in UACR. Adjustments as for Fig. 1A. A: Composite of major macrovascular, renal events and all-cause mortality. B:Majormacrovascular events. C:Major renal events. D: All-cause mortality. The circles represent the points at which knots were placed (0.25, 0.5, 1, 2, and 4-fold change). The areas shaded in grey represent the 95%confidence intervals. (A high-quality color representation of this figure is available in the online issue.) Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time. Diabetes Care 2018;41:163–170

Empagliflozin Reverses the Initial Decline in eGFR Renal function trajectory in the EMPA-REG OUTCOME trial. In this study, 7020 patients with T2DM at high cardiovascular risk were randomly assigned to receive the SGLT2 inhibitor empagliflozin (10 or 25 mg once daily) or placebo. After an initial drop in eGFR documented at week 4, renal function stabilized in empagliflozin-treated patients over the ensuing follow-up period, whereas among those patients receiving placebo, a steady decline of 1.67 ml/min per 1.73m2 per year in eGFR was observed. After 34 days of cessation of the study drug, the initial decrease in eGFR in all empagliflozin-treated patients was completely reversed with an adjusted mean difference from placebo in the change from baseline eGFR of 4.7 ml/min per 1.73 m2 (not depicted). Adapted from Wanner and colleagues.86 J Am Soc Nephrol 2017;28:1023–1039

Empagliflozin Significantly Decreased Albuminuria vs. Placebo Urinary albumin-to-creatinine ratio over 192 weeks Prespecified endpoint and post-hoc analyses in patients with (A) normoalbuminuria, (B) microalbuminuria, and (C) macroalbuminuria at baseline. Adjusted geometric mean values and 95% CIs are shown. Mixed-model repeated measures analysis using all data obtained until study end in patients treated with at least one dose of study drug. Normoalbuminuria: urinary albumin-to-creatinine ratio (UACR) <30 mg/g. Microalbuminuria: UACR ≥30 to ≤300 mg/g. Macroalbuminuria: UACR >300 mg/g. Only patients with post-randomisation measurements are included in the figure. *Placebo-corrected adjusted geometric mean ratio (95% CI) of relative change from baseline with empagliflozin. 164 weeks (IQR 115–186) corresponds to the median observation period. Lancet Diabetes Endocrinol 2017;8:610-621

Definitions of “Albuminuria” Normo- albuminuria Micro-albuminuria Macro- albuminuria Urine albumin/ creatinine ratio ‘UACR’ (mg/g creatinine) < 30 30 - 300 > 300 Definitions of Microalbuminuria and Macroalbuminuria Measurements of urinary albumin are made from either a timed (4 or 24 hours) urine collection or from a randomly voided “spot” urine. In the former case the urinary albumin concentration is divided by the time of the collection (in minutes) calculate the first parameter. In the latter case, both albumin and creatinine concentrations are measured in the same specimen and a ratio of albumin to creatinine calculated. Numerous studies have demonstrated that the values obtained from both timed and randomly collected specimens correlate well and have the same prognostic significance. Measurements of urine protein concentrations by “dipstick” chemistry are not sufficiently sensitive to identify urine albumin concentrations that meet the criteria for microalbuminuria. Protein in the urine is usually a combination of albumin, globulins, and Tamm-Horsfall protein derived from tubular secretion. References: Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999;34(6):973-995. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35(4suppl1):S97-S105. Diabetes Care 2004;27:S79-S83

Urine Albumin Creatinine Ratio (UACR)* and CVD Risk Risk when UACR > 7.5 mg/g creatinine in women and > 4.0 mg/g creatinine in men End Point CV event Hazard ratio 2.92 “p” <0.001 *simple, inexpensive, independent predictor of CVD Circulation 2005;112:969-975

Urine Albumin/Creatinine Ratio (UACR) < 7.5 Women < 4.0 Men Treatment Targets for Diabetic Renal Disease With Hypertension The results of clinical trials in diabetic patients at increased risk for cardiovascular and renal events suggest that aggressive control of hypertension may be the most cost-effective in reducing these risks, followed, in rank order, by aggressive management of dyslipidemia, and then by tight blood glucose control. References: Agarwal R. Treatment of hypertension in patients with diabetes: lessons from recent trials. Cardiol Rev. 2001;9(1):36-44. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.

Estimated GFR (eGFR) Normal 95 (ML/MIN/1.73M2) Abnormal <60/>105 Treatment Targets for Diabetic Renal Disease With Hypertension The results of clinical trials in diabetic patients at increased risk for cardiovascular and renal events suggest that aggressive control of hypertension may be the most cost-effective in reducing these risks, followed, in rank order, by aggressive management of dyslipidemia, and then by tight blood glucose control. References: Agarwal R. Treatment of hypertension in patients with diabetes: lessons from recent trials. Cardiol Rev. 2001;9(1):36-44. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.